Join
Live feed
·
PRReleasevia Quantisnow
Turn Therapeutics Inc. logo

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

ByQuantisnow·Wall Street's wire, on your screen.
TTRX· Turn Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TTRX (Turn Therapeutics Inc.) and more on Quantisnow.